Skip to content

US · FBRX · BIOTECHNOLOGY

Forte Biosciences, Inc. (FBRX) intrinsic value and stock valuation

$76.99as of 2026-11-21 · Mkt cap 1.57B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Forte Biosciences, Inc. DCF and intrinsic value

InvestorsCraft values FBRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from FBRX’s statements →

Forte Biosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Dallas, TX 75247 fortebiorx.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$0.00
20152025
Net income
-$-69.38M
20152025
Free cash flow
-$-51M
20152025
Total equity
$61M+0.7% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-70.66M-$-36.6M-$-32.49M-$-13.9M-$-21.49M
Net income-$-69.38M-$-35.48M-$-31.48M-$-13.86M-$-21.71M
EPSd-$-471.4K-$-12.15M-$-24.98M-$-19.8M-$-38.77M
Operating cash flow-$-50.88M-$-30.75M-$-28.71M-$-8.19M-$-16.68M
Capital expenditure-$-120K-$-40K-$-90K$0.00$0.00
Free cash flow-$-51M-$-30.78M-$-28.79M-$-8.19M-$-16.68M
Total assets$82.8M$61.6M$39M$42M$43.3M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-76.96M-$-22.24M-$-11.96M-$-41.1M-$-42.04M
Total equity$61M$52.5M$35.3M$38.8M$41.6M
Cash and short-term investments$77M$58.4M$37.1M$41.1M$42M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$60K$40K$10K$0.00$40K
Gross profit-$-60K-$-40K-$-10K$0.00-$-40K
Research and development expenses$58.3M$21.2M$21.9M$5.59M$13.9M
Selling, general and administrative expenses$12.4M$15.4M$10.6M$8.3M$7.63M
Other expenses$0.00$0.00-$0.00$20K$0.00
Operating expenses$70.7M$36.6M$32.5M$13.9M$21.5M
Cost and expenses$70.7M$36.6M$32.5M$13.9M$21.5M
Interest income$2.71M$1.31M$1.12M$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$60K$40K$10K$40K$40K
Ebitda-$-68.27M-$-35.44M-$-31.47M-$-13.84M-$-21.67M
Operating income-$-70.66M-$-36.6M-$-32.49M-$-13.9M-$-21.49M
Total other income/expenses, net$2.32M$1.12M$1.01M$20K-$-220K
Income before tax-$-68.34M-$-35.48M-$-31.48M-$-13.88M-$-21.71M
Income tax expense$1.04M$0.00$0.00$0.00$0.00
Net income-$-69.38M-$-35.48M-$-31.48M-$-13.86M-$-21.71M
Weighted average shares outstanding$147.2M$2.92M$1.26M$700K$560K
Weighted average diluted shares outstanding$147.2M$2.92M$1.26M$700K$560K
Balance sheet
20252024202320222021
Cash and short-term investments$77M$58.4M$37.1M$41.1M$42M
Net receivables$820K$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$80.6M$61.4M$38.3M$41.5M$42.5M
Property, plant and equipment, net$130K$80K$110K$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.19M$210K$650K$490K$790K
Total assets$82.8M$61.6M$39M$42M$43.3M
Accounts payable$9.99M$4.88M$1.42M$1.15M$950K
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$20.8M$9.08M$3.67M$3.18M$1.76M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.04M$0.00$0.00$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$21.8M$9.08M$3.67M$3.18M$1.76M
Common stock$10K$10K$40K$20K$10K
Retained earnings-$-223.37M-$-154M-$-118.52M-$-87.04M-$-73.17M
Accumulated other comprehensive income (loss)$0.00$10K$0.00$0.00-$-43.31M
Total equity$61M$52.5M$35.3M$38.8M$41.6M
Total investments$0.00$36.1M$25.2M$0.00$0.00
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-76.96M-$-22.24M-$-11.96M-$-41.1M-$-42.04M
Cash flow statement
20252024202320222021
Net income-$-69.38M-$-35.48M-$-31.48M-$-13.88M-$-21.71M
Depreciation and amortization$60K$40K$10K$0.00$40K
Stock-based compensation$6.26M$3.1M$3.28M$4.01M$4.21M
Change in working capital$11.4M$1.76M-$-390K$1.68M$720K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$5.54M$3.02M$270K$210K-$-290K
Net cash provided by operating activities-$-50.88M-$-30.75M-$-28.71M-$-8.19M-$-16.68M
Investments in property, plant and equipment-$-120K-$-40K-$-90K$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$36.2M-$-35.99M$50K$0.00$0.00
Common stock issued$76.8M$53M$24.7M$7.23M$60K
Common stock repurchased$0.00-$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$69.4M$51.9M$24.7M$7.24M-$-40K
Net change in cash$54.7M-$-14.88M-$-3.98M-$-940K-$-16.72M
Cash at end of period$77M$22.2M$37.1M$41.1M$42M
Operating cash flow-$-50.88M-$-30.75M-$-28.71M-$-8.19M-$-16.68M
Capital expenditure-$-120K-$-40K-$-90K$0.00$0.00
Free cash flow-$-51M-$-30.78M-$-28.79M-$-8.19M-$-16.68M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Forte Biosciences, Inc.

        Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.

        CEO
        Paul A. Wagner
        Employees
        22
        Beta
        2.84

        Explore

        Frequently asked questions

        What is the intrinsic value of Forte Biosciences, Inc. (FBRX)?

        InvestorsCraft does not currently publish an intrinsic value for FBRX. How the IC value is calculated.

        Is FBRX undervalued?

        InvestorsCraft does not publish an undervaluation signal for FBRX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.